Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 15/20 | 0.42 |
| ▸ | HTR1A | P08908 | 14/20 | 0.42 |
| ▸ | HTR2A | P28223 | 14/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGAV | P06756 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18194093 | 0.83 | PDE3B (0.43) | PDE3BPDE3ADRD2HTR1AHTR2A | |
| SCHEMBL24664739 | 0.78 | DRD2 (0.49) | PDE3BPDE3ADRD2HTR1AHTR2A | |
| SCHEMBL14984332 | 0.78 | MAOA (0.43) | PDE3BPDE3ADRD2HTR1AHTR2A | |
| SCHEMBL4148301 | 0.74 | PDE3B (0.43) | PDE3BPDE3ADRD2HTR1AHTR2A | |
| SCHEMBL21671865 | 0.74 | PDE3B (0.43) | PDE3BPDE3ADRD2HTR1AHTR2A | |
| SCHEMBL5366571 | 0.74 | CA9 (0.47) | PDE3BPDE3ADRD2HTR1AHTR2A | |
| SCHEMBL4132924 | 0.74 | PDE3B (0.50) | PDE3BPDE3ADRD2HTR1AHTR2A | |
| SCHEMBL5371747 | 0.74 | PDE3B (0.43) | PDE3BPDE3ADRD2HTR1AHTR2A | |
| SCHEMBL18202413 | 0.74 | PDE3B (0.43) | PDE3BPDE3ADRD2HTR1AHTR2A | |
| SCHEMBL5316288 | 0.73 | CRBN (0.41) | PDE3BPDE3ADRD2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060041123-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041123-A1 | Antibacterial agents | NQO2, NRDC, IFNG | PDE3B 2564/4885PDE3A 2995/4885DRD2 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.